Article:The role of splenectomy in lipid metabolism and atherosclerosis (AS) (6094557)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q58775453. Its title is The role of splenectomy in lipid metabolism and atherosclerosis (AS) and the publication date was 2018-08-16. The initial author is Xiao-Ming Ai.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Lipids in Health and Disease

The role of splenectomy in lipid metabolism and atherosclerosis (AS)

  • Xiao-Ming Ai
  • Li-Chen Ho
  • Lu-Lu Han
  • Jin-Jing Lu
  • Xiong Yue
  • Nian-Yin Yang

Publication date (epub): 8/2018

Publication date (pmc-release): 8/2018

Publication date (collection): /2018

Abstract

The extensive performance of splenectomy worldwide for patients suffered from splenic trauma has given rise to high risks of postoperative complications, which has been attracting increasing attention in recent years. Nowadays the spleen is regarded as a versatile organ of the human body, invested with various excellent properties. The spleen has been recognized to take a great part in lipid metabolism. While removal of the spleen intends to alter lipid values, especially with an elevated LDL, splenic autotransplantation is able to normalize these lipid alterations. What is more, conservative surgical procedures like subtotal or partial splenectomy, could as well, afford a correction of dyslipidemia. At the same time, clinically, splenectomy demonstrates a high rate of atherosclerosis (AS), whereas non-surgical treatment after splenic trauma shows unchanged propagation of AS. Based on the intimate relationship between serum lipids and AS, the lipid changes modulated by splenectomy are believed to be responsible for the development of AS. Therefore, a “splenic factor” is most likely present in the regulation of lipidation and AS. Several theories have been postulated to elucidate the possible mechanism involved, among which most are primarily based on its forceful natural immune function, that is to say, the mononuclear phagocytic system.However, the accurate mechanisms behind this mysterious phenomenon still remain unclear so far. Of importance, lipid fractions should be monitored consecutively in case of inevitable splenectomy.

Paper

Background

Insufficient knowledge about the spleen had popularized the performance of splenectomy during the past decades, particularly for patients suffered from splenic injuries, until complications ensued gradually one after another in the subsequent years, among which some would be even severe and fatal. The most worrisome is the overwhelming postsplenectomy infection (OPSI), which is characterized as fulminant sepsis caused by encapsulated bacteria [[1]]. OPSI could occur months, years, even decades later, in particular in children and younger adults, accompanied by a morbidity of approximately 4% and mortality of 2% [[2]]. Reactive thrombocytosis is another serious concern after splenectomy, showing a reported prevalence of up to 75% [[3]]. Not only does it directly contribute to venous thromboembolism [[3]], and more seriously, disseminated intravascular coagulation (DIC), but can it also pose endothelial damage and the subsequent etiology of pulmonary hypertension in the long run [[4]].

Awakened by the growing awareness of the potential complications following splenectomy, more and more surgeons have paid special attention to the importance of spleen, and have already recognized it as a useful organ of the human body, invested with various excellent properties. To date, it has been well known that the spleen is endowed with powerful filtration, immunological, along with hematopoietic and storage functions [[5]]. Removal of the spleen would favor a series of dysfunctions [[6]]. Furthermore, importantly, the spleen takes a great part in metabolic control, which has been attracting increasing attention in recent years, especially in the aspect of lipid metabolism. In general, the spleen takes on a substantial proportion of the organic metabolism and removal of the spleen would obliterate most of the invaluable gifted functions, predisposing to different diseases [[7][15]]. Apart from the afore-mentioned OPSI and thrombocytosis, asplenism is meanwhile associated with a high risk of vascular events especially as atherosclerosis (AS) and coronary artery disease, diabetes mellitus [[16]], as well as acute pancreatitis [[17]] and cancers [[18]].

Initial recognition of a splenic influence on lipid metabolism

It has been well established that the spleen is devoted to a wide spectrum of metabolic control, including the metabolism of all metals, albuminoids alongside with indirect bilirubins from senescent erythrocytes [[19]]. As a matter of fact, the spleen does also participate in lipid metabolism, but our knowledge about it is very limited.

In 1914, King reported an increase in plasmatic cholesterol levels after splenectomy in dogs [[20]]. Supposedly, there seemed to be a possible splenic influence on cholesterol manipulation. However, it was only many decades later that did this problem begin to attach emphasis. Asai et al. detected increased densities of cholesterols, triglycerides (TG) and phospholipids (PL), in conjunction with decreased HDL after removal of the spleen in rabbits [[11]]. Thereafter, a great many studies have documented elevated lipid parameters in splenectomized rodent models [[9], [12], [21][25]], although some of them might have achieved diverse results.

At the same time, while splenectomy tended to alter lipid values in animals, splenic autotransplantation was able to normalize these lipid alterations [[21], [23], [25], [26]]. Moreover, conservative surgical procedures, like subtotal or partial splenectomy, could as well, afford a correction of dyslipidemia [[25][28]].

Clinically, the spleen does interfere with the evolution of some diseases associated with lipid disorders. It is the lysosomes of cells of the mononuclear phagocytic system in the spleen that are most frequently present with metabolic changes in times of lipid deposits [[27]]. Take Gaucher’s disease for example, it is characterized by lipid-loaded cells known as Gaucher cells due to the anomalous accumulation of PL, and is manifested with splenomegaly [[27]]. Comparable splenic manifestations can also be uncovered in other etiologies like Niemann-Pick’s disease, gangliosidoses as well as Fabry disease [[7]].

Splenomegaly is inclined to maneuver the cholesterolemia over against splenectomy, which is most likely to develop hypocholesterolemia as a consequence of overfunction of the mononuclear phagocytic system [[13]]. Myeloproliferative disorders like polycythemia vera and myelofibrosis, are usually accompanied by hypersplenism and splenomegaly, displaying a reduction of serum cholesterol profiles [[27]]. By comparism, splenectomy is capable of reversing these cholesterol alterations [[8], [9], [13], [14]]. Moreover, in other diseases such as Gaucher’s disease [[15]] and type B thalassemia major [[10]], similar results could be obtained likewise.

In light of these available findings, we have reasons to believe that the spleen participates in lipid metabolism to an extreme extent, although lack of adequate convincing evidences. Therefore, a “splenic factor” proposed by Asai et al. [[12]] is most likely present in the regulation of lipidation, just as illustrated in Fig. 1.Fig. 1

a flow diagram illustrating a splenic factor in lipid metabolism

Initiate recognition of the impact of splenectomy on lipid metabolism and AS

AS is the leading cause of cardiovascular disease (CVD), which most of the time features acute heart attack and stroke [[29]], and accounts for the soaring morbidity and mortality worldwide [[30]]. The pathogenesis of AS is very complex, involving a variety of risk factors and mediators, among which the circulating cholesterol concentrations remain as the most important ones, especially LDL and HDL [[29]]. In fact, elevated serum TG and LDL, together with reduced HDL, are well identified as the atherogenic lipid triad [[27]]. Generally speaking, AS is a metabolic disease in essence, which is, as a result of lipid disorders, characterized by lipid deposition in the intimal layer of arteries as well as atheromatous plaque formation [[10]].

In 1977, the long-term observation of veterans subjected to tramatic splenectomy during World War II disclosed an intensive susceptibility to coronary atherosclerotic heart disease [[31]]. Based on the close relationship between serum lipids and AS, the lipidic metabolic changes modulated by splenectomy were believed to be responsible for the rising mortality due to acute myocardial stroke [[9], [32]], thus leading to the essential investigations of the possible modulating role of spleen in lipid disorders and AS.

As expected, it seemed extremely evident in animals [[10], [12], [22], [25], [33]] that removal of the spleen worsened lipid metabolism and accelerated AS. Clinically, patients submitted to traumatic splenectomy demonstrated a high rate of hyperlipidemia together with AS or acute myocardial infarction [[9], [25], [34], [35]]. On the contrary, while in individuals suffered from hereditary spherocytosis (HS), splenenctomy exhibited high atherosclerotic lesions [[35]], a preserved spleen could allow low adverse arterial events [[36]]. In the meantime, patients dealed with non-surgical treatment after splenic trauma showed unchanged propagation of AS [[34]].

Therefore, it is justified to speculate that, the absence of spleen apparently determines the occurrence of AS on account of deterioration of serum lipids, indicating a protective splenic effects [[33]].

Results of determination of serum lipid concentrations upon splenectomy

A number of studies have been carried out to evaluate influence of the spleen in lipid manipulation, which however, have created different and controversial results, with a vast preponderance of elevated lipid parameters by splenectomy.

Experimentally, the majority of studies have provided evidences of increased concentrations of TG, TC, LDL, and decreased HDL, in combination with promotion of atherosclerotic changes in the absence of spleen [[9], [12], [13], [23], [25], [27]], although with some variations, which alleged no alterations in TG or VLDL fractions [[13], [25], [27]]. Nonetheless, there are exceptions. Some researchers peculiarly pointed out an elevation of all lipid parameters upon removal of the spleen [[22], [26], [27]]. In contrast, some others proved no abnormaly in LDL regardless of the increment in other lipid fractions [[12], [23]]. What is more, some else even reported a declining tendency of LDL in opposition to the rise of other fractions [[37]].

Clinically, splenectomy is equally coupled with a capability of modifying lipid values, especially with an elevated LDL [[13], [14], [28]].

On the other hand, apart from the above-mentioned lipid disturbances, there are even discrepant outcomes. Some study revealed reduced LDL, and increased HDL [[37]], whereas others didn’t detect any significant changes in lipid parameters [[10], [38][40]], among which some exhibited enhanced atherosclerotic lesions [[10], [38], [39]], and the remaining was even in favor of attenuated coronary artery atherosclerosis [[40]]. Furthermore, there are still few studies reflecting no abnormalies in plasmatic lipid indices and atherogenesis at all [[24], [41]].

Therefore, the role of spleen in lipid metabolism and AS still remains debated, irrespective of the strong supportive evidences.

Effect of diet in lipid control

As in human being, a diet is the first-line management for plasmatic lipid levels and cardiovascular disease [[42]], it could also exert a similar action in lipid control in splenectomized animals despite of lack of appropriate clinical trials [[41]], and in this respect, fatty components in a diet could be more effective than cholesterol [[30]]. Researches have verified that the types of chow were able to augment the alterations in lipid profiles by splenenctomy [[9], [26]].

Once again, some other voices arise representing different standpoints. An author argued that worsening of lipid fractions was entirely ascribed to the quality of chow other than splenectomy in rats [[41]]. In contrast, another one insisted that the very lipidic abnormaly was intrinsically relevant to the spleen, not the diet at all [[32]]. Hence, dissents will continue within this context.

The possible mechanisms

The plasma lipids are fats or complex fat-like molecules, mainly referring to triglycerides, cholesterols, as well as phospholipids (PL) and free fatty acids (FFA). In brief, the process of lipid metabolism encompasses digestion and absorption in the small intestine, transportation within lipoproteins through the blood, and then biosynthesis in the liver. It is extremely intricate and subtle, requiring the help of a great deal digestive enzymes, and the liver is the pivotal organ during this course. Trouble in any steps of this process is likely to bring about lipid metabolism disorders, which are associated with an increase in the concentrations of plasma lipids.

Among the numerous studies focused on dyslipidemia upon splenectomy, very few conferred deep insight into the mechanism implicated in lipid regulation by the spleen, thus further acting on the development of AS. There is still a long way for us to completely unveil its mysterious piths. Several theories have been postulated to elucidate the possible mechanism, among which most are primarily based on its forceful natural immune function, in other words, the mononuclear phagocytic system. But none of them have been well accepted. On the other hand, a number of potential predisposing factors different from lipid dysfunctions, like disturbance in coagulation, abnormal macrophage involvement in the plaque [[40]], in combination with some other factors, could be also validated in the regulation process. Thence, no consensus has been attained so far.

Lipid reservoir

The most common and popular explanation was initially proposed by Schmidt et al., comparing the spleen to a storage reservoir for lipids [[8]]. In case of hypersplenism, the splenic macrophages accumulate a large proportion of fat through hyperactive phagocytosis, resulting in hypolipidemia, while splenectomy can engender an inverse effect, provoking reversal in serum lipid densities [[37]]. Accordingly, it is well known as a splenic factor involved in lipid control (as shown in Fig. 1), suggested by Asai et al. [[12]]. This theory seemingly covers both the macrophage activity and the available splenic volume. In states of splenomegaly, overloaded splenic tissue exaggerates the impact of the splenic factor by phagocytosis, with dramatically rising storage volume for lipid, thus lowering serum lipid values [[43]], whereas in an asplenic or hyposplenic condition, this very mentioned factor is missed, the splenic parenchyma as well as the macrophage activity undergoes destruction, and the metabolic reactions meet with repercussion, thus improving lipid parameters [[27]]. However, this theory is unable to fully interpret the currently existent evidences of lipidic metabolic changes in splenic cells, thus necessitating an in-depth investigation into its innate cellular function.

The mononuclear phagocyte system against lipid fractions

From a metabolic point of view, the spleen has been established as an important site of LDL catabolism by the efficient macrophage activity [[31]]. It has been hypothesized that in the event of splenomegaly, hypocholesterolemia would take place through amplified LDL catabolism, as a result of overfunction of macrophage activity [[44]]. According to this theory, in the presence of the spleen, this instinctive auto-immune effect imposes on the structures of lipoproteins, extraordinarily HDL and LDL, giving rise to their plasmatic purification and conversion into foamy cells [[10], [15], [33]], which is accompanied by hypocholesterolemia. Conversely, in the absence of the spleen, lack of macrophage impairs the clearance mechanism, leading to the corresponding reduced catabolism together with the attendant hypercholesterolemia [[22]].

Noticeably, it needs to figure out that the liver is the principle organ in view of lipoprotein synthesis and excretion. The changes in lipid parameters by splenectomy are more likely to originate from exaggerated hepatic production of triglyceride-rich lipoproteins rather than attenuated catabolism, which would be more eligible to take charge of a decrement in HDL levels [[9]]. In parallel with this assumption, upon removal of the spleen, a reinforced LDL receptor (LDLR) activity is induced to counteract the attenuated LDL catabolism [[9]]. By binding to LDLR, LDL-LDLR complex is then endocytosed into the liver Kuppfer cells for degradation, and afterwards, LDLR would return to the cell surface for recirculation [[45]]. However, as another distinguished major lipid pathway [[45]], the degradation products may later on, be transported back to the liver for reutilization which are subsequently refabricated for relipidation, leading to a resultant augmented cholesterol load in hepatocytes [[9]]. As a consequence, synthesis of triglyceride-rich lipoproteins is augmented, especially as LDL, which in reverse, with the help of cholesteryl ester transfer protein (CETP) [[46], [47]], are able to propel the final selective removal of nascent HDL by the liver, leading to lessened HDL densities [[48]]. Eventually, an exaggerated LDL in company with lessened HDL exacerbates atherogenensis.

Needless to say, the production along with purification of lipoproteins modulated by the spleen, is an extremely sophisticated course, and during this course, a variety of mediators may be drawn into. For instance, ATP-binding cassette (ABC) transporter ABCA1 favors macrophage cholesterol efflux to lipid-poor apolipoproteins like apoA-I [[49]], thus facilitating the production of HDL [[50]]. Deficiency of ABCA1 would accelerate atherosclerotic lesion development [[51]]. But whether ABCA1 plays a positive or negative influence on lipid control still remains unclear. Cholesteryl ester transfer protein (CETP) is responsible for the exchange of cholesteryl esters (CE) and TG between apoB-containing lipoproteins and HDL [[46], [47]], in parallel with an increment in LDL and decrement in HDL.

Anti-oxLDL antibodies

Authentically, AS has been declared to arise from vascular inflammation coupled with dyslipidemia, and LDL has been well considered as a risk factor for AS. Deposits of LDL in the arterial wall would aggravate the formation of atheromatous plaque. According to the oxidative theory [[52]], deposits of LDL as well as the subsequent oxidative modifications in the LDL molecules, pose damage to the vascular endothelium [[52]], initiating the atherosclerotic scenario. And a comprehensive interplay of the modified lipoproteins, such as oxidized LDL (oxLDL), macrophages, lymphocytes, in combination with normal cellular constituents of the arterial wall [[52]], perpetuates the progression of this disease. The atherosclerotic lesion attributes specific immune responses to oxLDL and other antigens [[38]].

The spleen has been established to be the staple organ responding to blood antigens, specifically to the oxLDL [[10], [33], [38]], stimulating the production of anti-oxLDL antibodies intermediated by B lymphocytes [[28], [38], [53]]. Based on this highly regulated phenomenon, some scholars would like to take advange of these antibodies to clarify a potential antibody-type protection against AS [[33], [38]]. The immune activity of circulating antibodies to oxLDL is able to evoke internalization of oxLDL into macrophages and its ultimate purification. By comparison, splenectomy is disposed to elimination of this valuable immune capability, giving rise to reduction of the oxLDL clearance and the subsequent aggravation of AS. Remarkably, experimental reports have indicated the association between an increment in anti-oxLDL antibody titers and a decrement in atherosclerotic lesions [[33], [38]].

By this token, the spleen is not only dedicated to the production of anti-oxLDL antibodies, but also to the clearance of antigen-antibody complexes [[43]]. However, unexpectedly, there are also few documentations affirming exacerbation of atherosclerotic lesions with no differences in serum titers of anti-oxLDL antibodies after splenectomy [[10], [39]]. Hence, the role of these antibodies in AS still has not been confirmed thus far [[53]], and what is more, it is not sensible to simply accredit the spleen’s participation in AS to the production of these antibodies [[10]].

Involvement of lipidic activities of the liver

The spleen may also interfere with the lipidic metabolic change of the liver on account of decreased lipid peroxidation following splenectomy [[22]]. As far as lipidic genesis, lipoproteins are mainly assembled and excreted in the liver and small intestines, exporting lipids (cholesterol, TG and PL) to the circulation system and in turn, importing excessive lipids to the liver for clearance or recycling [[45]]. The liver possesses enormous amounts of Kupffer cells, which primarily account for elimination of bacteria in conjunction with engulfment and clearance of lipoproteins via peroxidatic reaction [[22]]. Of note, splenectomy is liable to inhibit the responsiveness of Kupffer cells [[54]], thus bringing about dyslipidemia.

In addition, LDL receptors (LDLR) also partake in the modulation of dyslipidemia upon splenectomy. Upon removal of the spleen, enhanced LDLR activities are elicited in the liver [[9]], as mentioned above. It is believed that, LDLs, which transport most cholesterol, bind to LDLRs first, and then are uptaken and cleared in the liver or small intestine [[45]]. Just as anticipated, enhanced LDLR activities exacerbate LDLs clearance. Besides, chylomicron together with VLDL remnants are also swept away by specific liver receptors [[55]]. Thereby, there is an argument that disturbance of lipoprotein receptors in the liver may be as well in charge of dyslipidemia after splenectomy [[9]].

Lipoprotein lipase (LPL)

LPL, as an enzyme responsible for the transportation and storage of lipids as well as hydrolyzation of chylomicrons and TGs, is most active in the hepatocytes. It can be stimulated by ApoC-II and suppressed by ApoC-III [[56]]. Amazingly, LPL activity has been also found in the spleen. Under the condition of splenomegaly, high LPL activity has been testified to accelerate cholesterol deposition [[57]], thus offering an additional proof which supports the theory taking the spleen as a storage reservoir.

Shifts in MicroRNAs (miRNAs) expression

New-emerging disciplines on the noncoding sequences of miRNAs have corroborated their functions as the posttranscriptional regulation of gene expressions [[58]]. miRNAs have also been identified as pivotal regulators for lipid metabolism in recent years, playing an influence in AS [[59]]. Purportedly, a body of miRNAs have been proved to regulate genes correlated with HDL metabolism, especially miR- 33a/b [[60]], which may contribute to ABCA1 expression at the same time, while many others, such as miR-148a, miR-128-1, or miR-30c, are involved in controlling circulating LDL concentrations as well as hepatic LDLR expressions [[61]]. Shifts in miRNAs expression after splenectomy may possibly take part in the development of AS [[62]]. But the accurate mechanism remains still unclear.

The platelet (PLT) pathway

It is a very common phenomenon that PLT counts experience uprising upon splenectomy, which could otherwise be reverted under the conditions of splenic autotransplantation [[22], [27]]. It has been advocated that splenectomy may accelerate the progression of AS through the PLT pathway [[40]], independent of lipid dysfunction [[9], [25]]. Thrombocytosis in combination with hypercoagulability is prone to PLT accumulation and aggregation [[9]], and the subsequent thrombus formation within the arterial wall, acting as a causative factor for AS [[9]].

Immune-mediated mechanism

Needless to say, the spleen is a multipurpose organ, massively synthesizing and accommodating large quantities of granulocytes, megakaryocytes, alongside with lymphocytes and macrophages, which have been verified to make great contributions to the process of AS. It is the major organ obligated to lymphocytes in the human body, and assumes the duties of maintenance of the immune system, by regulating both local and systemic immunity [[63]].

Reportedly, a predominant number of memory B cells are pooled herein, which following activation, are apt to protect against atherosclerotic lesion formation [[64]], most probably through mitigation of the characteristic proinflammatory cytokine response of the T-helper 1 (Th-1) [[65]]. Large amounts of regulatory T cells (Tregs) are also harbored in the spleen, which can similarly repress AS [[66]], accompanied by biogenesis of a battery of other biomolecules [[38]]. Meanwhile, Th2 cells classically cultivated in the spleen, are mediated by B cells and antibodies, and substantially inhibit effects of Th1 cells [[10]], thus exerting protective impact on AS.

On the contrary, Th1 lymphocytes, which are responsible for IFN-γ production and macrophage activation [[67]], in conjunction with the activated macrophages, have already been attested to aggravate the atherogenesis throughout the whole process [[68]].

Taken altogether, it has even been declared that, following removal of the spleen, an integrated combination of macrophages, T cells together with an imbalance between the Th1/Th2 patterns [[64]], B cells, as well as their recruitments at the lesion site, is hypothesized to exclusively implement the mechanism, precluding any lipidic activities. Moreover, some authors have already observed atherogenic deterioration lack of serum lipid abnormalities in splenectomized rodent models, thus suggesting an immune-mediated mechanism, other than modulation of lipidation [[10]].

Adverse viewpoints

In contrast, certain explanations appear likewise plausible with respect to improvement of AS by splenectomy. Reportedly, the spleen is regarded as a key manufacturer for monocytes and the most critical section of the mononuclear phagocyte system. It has stated that in the setting of acute myocardial infarction, the spleen is capable of rapidly mobilizing large quantities of mononuclear phagocytes directly onto the endothelium in the vessel wall in response to acute inflammation [[69]]. Moreover, they can also trigger the massive macrophage recruitment in fatty streak lesions [[70]], thus introducing another contributing factor to AS. However, removal of the spleen would cut down circulating monocyte concentrations, giving rise to fewer monocytes arrest in the aortic plaque [[40]]. Ultimately, a shrunken inflammation could improve the atherosclerotic condition.

In addition, a characteristic infiltration of macrophages in the vascular tissue could be found in response to lipid deposited in the atherosclerotic lesions [[40]]. Theoretically, asplenism is linked with a decrement of macrophage densities. Nevertheless, exceptions arise once more. Some research has displayed mitigation of AS lacking decline in macrophage densities after removal of the spleen [[40]], but with modified distribution of macrophages across the plaque, media, and adventitia [[40]], which was also consistent with some other studies [[71]].

Conclusions

In view of the conflicting results alongside with the obscure mechanism, contradictions will persist in the future as regards the role of splenectomy in lipid control and AS, and more relevant experimental and clinical studies will be needed. With the growing recognition of the spleen being an important organ with versatile functions apart from its impact on metabolic control, multiple modalities of spleen-conserving procedures such as vascular occlusions, splenorrhaphies, as well as partial splenectomies, have been utilized in recent years, so as to preserve the splenic tissues. Splenic tissue autotransplantation is an effective approach to partially reconstitute its structure and function in case of unavoidable splenenctomy, which is substantially capable of restoring the lipid and platelet (PLT) parameters [[22], [27]]. Furthermore, it is worth noting that the non-surgical treatment for splenic trauma tends to gain better outcomes than surgery [[72]].

On the other hand, it should be admitted that this very role of splenectomy in dylipidemia and AS may be highly regulated, albeit extremely intricate. It involves probably the synergistic interactions between nutritional condition, immunologic response, as well as metabolic control and coagulation, and is in the meantime influenced by numerous other factors, such as demographics, poor diet, sedentary lifestyle, along with hormonal and genetic predisposition. Thereby, it is indeed problematic and challenging for clinicians to deal with, and lipid fractions should be monitored consecutively in patients subjected to splenectomy.

References

  1. IVB DeLBA ZarzavadjianH VuarnessonBN MunozB HalimiLaparoscopic partial splenectomy: a technical tipSurg Endosc2015291949910.1007/s00464-014-3638-z24962862
  2. AD SabatinoR CarsettiGR CorazzaPost-splenectomy and hyposplenic statesLancet20113789785869710.1016/S0140-6736(10)61493-621474172
  3. DH LeeG BarmparasN FierroBJ SunS AshrafianSplenectomy is associated with a higher risk for venous thromboembolism: a prospective cohort studyInt J Surg201524Pt A273210.1016/j.ijsu.2015.10.01126493210
  4. AV PalkarA AgrawalS VermaA IftikharEJ MillerPost splenectomy related pulmonary hypertensionWorld J Respirol201552697710.5320/wjr.v5.i2.6926949600
  5. I MikoN NemethK PetoA FurkaL TothChanges of red blood cell aggregation parameters in a long-term follow-up of splenectomy, spleen-autotransplantation and partial or subtotal spleen resections in a canine modelClin Hemorheol Microcirc20176719110010.3233/CH-17026428598833
  6. I MikoN NemethS Sipka JrE BrathK PetoA GulyasI FurkaR ZhongHemorheological follow-up after splenectomy and spleen autotransplantation in miceMicrosurgery2006261384210.1002/micr.2020816444721
  7. A PetroianuRG da SilvaV Nascimento CardosoLR AlbertiMG da SilvaEffect of spleen surgeries on Escherichia coli distribution on the mononuclear phagocytic systemInt J Surg201081485110.1016/j.ijsu.2009.10.00619854304
  8. HH SchmidtS WagnerM MannsThe spleen as a storage pool in lipid metabolismAm J Gastroenterol199792610729177547
  9. M FatourosK BourantasE BairaktariM ElisafO TsolasD CassioumisRole of the spleen in lipid metabolismBr J Surg199582121675167710.1002/bjs.18008212308548239
  10. AB RezendeNN NetoLR FernandesAC RibeiroJI Alvarez-LeiteHC TeixeiraSplenectomy increases atherosclerotic lesions in apolipoprotein E deficient miceJ Surg Res20111712e231e23610.1016/j.jss.2011.08.01021962813
  11. K AsaiT HayashiM KuzuyaC FunakM NaitoF KuzuyaDelayed clearance of beta-very low density lipoprotein after feeding cholesterol to splenectomized rabbitsArtery199018132462085285
  12. K AsaiM KuzuyaM NaitoC FunakiF KuzuyaEffects of splenectomy on serum lipids and experimental atherosclerosisAngiology198839649750410.1177/0003319788039006023377269
  13. M AviraniJG BrookI TatarskyY LevyA CarterIncreased low-density lipoprotein levels after splenectomy: a role for the spleen in cholesterol metabolism in myeloproliferative disordersAm J Med Sci19862911252810.1097/00000441-198601000-000063942157
  14. HS GilbertH GinsbergR FargerstromWV BrownCharacterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activityAm J Med198171459560210.1016/0002-9343(81)90212-67282748
  15. L RennerD von SoostenA SipkaS DöllA BeinekeHJ SchuberthS DänickeEffect of conjugated linoleic acid on proliferation and cytokine expression of bovine peripheral blood mononuclear cells and splenocytes ex vivoArch Anim Nutr2012662738510.1080/1745039X.2012.67221822641921
  16. S-C WuC-Y FuC-H MuoY-J ChangSplenectomy in trauma patients is associated with an increased risk of postoperative type II diabetes: a nationwide population-based studyAm J Surg2014208581181610.1016/j.amjsurg.2014.03.00324928333
  17. S-W LaiC-L LinK-F LiaoSplenectomy correlates with increased risk of acute pancreatitis: a case-control study in TaiwanJ Epidemiol201626948849210.2188/jea.JE2015021427087607
  18. K SalavouraA KolialexiG TsangarisA MavrouDevelopment of cancer in patients with primary immunodeficienciesAnticancer Res2008282B1263126918505064
  19. P MargetisM AntonelouF KarababaA LoutradiL MargaritisI PapassideriPhysiologically important secondary modifications of red cell membrane in hereditary spherocytosis-evidence for in vivo oxidation and lipid rafts protein variationsBlood Cells Mol Dis200738321022010.1016/j.bcmd.2006.10.16317208471
  20. JH KingStudies in the pathology of the spleenArch Intern Med191414214516710.1001/archinte.1914.00070140002001
  21. DN Salomao-PauloA Lazaro-da-SilvaThe plasma lipids after total and partial splenectomy in dogsRev Col Bras Cir200128426427010.1590/S0100-69912001000400006
  22. AA AkanN SengülS SimşekS DemirerThe effects of splenectomy and splenic autotransplantation on plasma lipid levelsJ Investig Surg200821636937210.1080/0894193080243889819160147
  23. FC SimõesRG MarquesCF DiestelCER CaetanoAPG DinisNL HorstLipidic profile among rats submitted to total splenectomy isolated or combined with splenic autotransplantActa Cir Bras20072222 Suppl 1465110.1590/S0102-8650200700070001017505655
  24. BL DemunerGZ PinhoJC ThomazNP StegmillerRM MendesEffect of total splenectomy in the lipid profile in miceActa cirúrgica brasileira/Sociedade Brasileir201530530631210.1590/S0102-865020150050000001
  25. A PetroianuDF VelosoGR CostaLR AlbertiEffects of splenic surgeries on lipidogram of ratsRev Assoc Med Bras2006521565910.1590/S0104-4230200600010002416622541
  26. IC Lemos-PauloDN Salomao-PauloA Lazaro-da-SilvaRM FolettoGL ColnagoPM VargasPlasmatic lipids levels in rats after total splenectomy, simultaneous ligature of the splenic vessels, and subtotal splenectomy with inferior pole preservationRev Col Bras Cir200532522923610.1590/S0100-69912005000500003
  27. A PetroianuDF VelosoLR AlbertiL de Souza VasconcellosPlasma lipid alterations after total splenectomy, subtotal splenectomy and splenic auto-implants in ratsJ Gastroenterol Hepatol2008237pt222122410.1111/j.1440-1746.2007.05263.x
  28. DN PauloIC PauloAA MoraisM KalilAJ GuerraGL ColnagoJ FaintuchIs splenectomy a dyslipidemic intervention? Experimental response of serum lipids to different diets and operationsMicrosurgery200929215416010.1002/micr.2056818942648
  29. CK GlassJL WitztumAtherosclerosis. The road aheadCell2001104450351610.1016/S0092-8674(01)00238-011239408
  30. EJ SchaeferLipoproteins, nutrition, and heart diseaseAm J Clin Nutr200275219120210.1093/ajcn/75.2.19111815309
  31. CD RobinetteJF Fraumeni JrSplenectomy and subsequent mortality in veterans of the 1939–45 warLancet19772802912712910.1016/S0140-6736(77)90132-569206
  32. TS RosaCEN AmorimCC BarrosAS HaroF WasinskiRole of leptin in body temperature regulation and lipid metabolism following splenectomyNeuropeptides201554677210.1016/j.npep.2015.10.00626526226
  33. JL WitztumSplenic immunity and atherosclerosis: a glimpse into a novel paradigm?J Clin Invest2002109672172410.1172/JCI021531011901180
  34. MS TsaiSE ChouHS LaiLB JengCL LinCH KaoLong-term risk of acute coronary syndrome in splenectomized patients due to splenic injuryMedicine2015949e61010.1097/MD.000000000000061025738485
  35. RF SchillingSpherocytosis, splenectomy, strokes, and heart attacksLancet199735090921677167810.1016/S0140-6736(05)64276-69400518
  36. RF SchillingRisks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis - a personal viewBr J Haematol2009145672873210.1111/j.1365-2141.2009.07694.x19388926
  37. M SitEE YilmazM TosunG AktasEffects of N-acetyl cysteine on lipid levels and on leukocyte and platelet count in rats after splenectomyNiger J Clin Pract201417334334510.4103/1119-3077.13023724714014
  38. G CaligiuriAP NicolettiB PoirierGK HanssonProtective immunity against atherosclerosis carried by B cells of hypercholesterolemic miceJ Clin Invest2002109674575310.1172/JCI727211901183
  39. L BartY ZhaoAC FoksRB HildebrandK JohanLeukocyte ABCA1 remains Atheroprotective in Splenectomized LDL receptor knockout micePLoS One2012710e4808010.1371/journal.pone.004808023133551
  40. Y LiJR StoneThe impact of splenectomy on human coronary artery atherosclerosis and vascular macrophage distributionCardiovasc Pathol201625645346010.1016/j.carpath.2016.08.00127614166
  41. AP DinisRG MarquesFC SimõesCF DiestelCE CaetanoPlasma lipid levels of rats fed a diet containing pork fat as a source of lipids after splenic surgeryLipids200944653754310.1007/s11745-009-3302-x19415360
  42. AH LichtensteinLJ AppelM BrandsM CarnethonS DanielsHA FranchB FranklinP Kris-EthertonWS HarrisB HowardN KaranjaM LefevreL RudelF SacksL Van HornM WinstonJ Wylie-RosettDiet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association nutrition committeeCirculation20061141829610.1161/CIRCULATIONAHA.106.17615816785338
  43. TB GonçalvesVN YamakiDH FeijóLE SouzaE SilveiraEffects of splenic allograft in lipid profile of non-splenectomized rats: the immune and metabolic role of the “double spleen”Revista Do Colégio Brasileiro De Cirurgiões201441212212710.1590/S0100-6991201400020000924918726
  44. NA LeJC GibsonA RubinsteinGA GrabowskiHN GinsbergAbnormalities in lipoprotein metabolism in Gaucher type 1 diseaseMetabolism198837324024510.1016/0026-0495(88)90102-33125406
  45. D GaudetJP DrouinchartierP CoutureLipid metabolism and emerging targets for lipid-lowering therapyCan J Cardiol201733787288210.1016/j.cjca.2016.12.01928365054
  46. P BarterCETP and atherosclerosisArterioscler Thromb Vasc Biol20002092029203110.1161/01.ATV.20.9.202910978244
  47. GJ de GroothAH KlerkxES StroesAF StalenhoefJJ KasteleinJA KuivenhovenA review of CETP and its relation to atherosclerosisJ Lipid Res200445111967197410.1194/jlr.R400007-JLR20015342674
  48. A BhattA RohatgiHDL cholesterol efflux capacity: cardiovascular risk factor and potential therapeutic targetCurr Atheroscler Rep2016181210.1007/s11883-015-0554-126710794
  49. JF OramRM LawnMR GarvinDP WadeABCA1 is the cAMPinducible apolipoprotein receptor that mediates cholesterol secretion from macrophagesJ Biol Chem200027544345083451110.1074/jbc.M00673820010918070
  50. K-A RyePJ BarterFormation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-IArterioscler Thromb Vasc Biol200424342142810.1161/01.ATV.0000104029.74961.f514592845
  51. RJ AielloD BreesP-A BourassaL RoyerS LindseyIncreased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophagesArterioscler Thromb Vasc Biol200222463063710.1161/01.ATV.0000014804.35824.DA11950702
  52. D SteinbergThe LDL modification hypothesis of atherogenesis: An updateJ Lipid Res200950SupplS37610.1194/jlr.R800087-JLR20019011257
  53. S TsimikasES BrilakisRJ LennonER MillerJL WitztumRelationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular eventsJ Lipid Res200748242510.1194/jlr.M600361-JLR20017093289
  54. M HoekstraR OutJK KruijtM Van EckTJ Van BerkelDiet induced regulation of genes involved in cholesterol metabolism in rat liver parenchymal and Kupffer cellsJ Hepatol200542340040710.1016/j.jhep.2004.11.03215710224
  55. TE WillnowZ ShengS IshibashiJ HerzInhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonistScience199426451641471147410.1126/science.75151947515194
  56. HN GinsbergWV BrownApolipoprotein CIII: 42 years old and even more interestingArterioscler Thromb Vasc Biol201131347147310.1161/ATVBAHA.110.22184621325666
  57. Mayes PA. Lipid transport and storage, in edit Murray RK. Harper’s Biochemistry. Am J Med. 1996;25(3):254–70.
  58. DP BartelMicroRNAs: target recognition and regulatory functionsCell2009136221523310.1016/j.cell.2009.01.00219167326
  59. B AryalAK SinghN RotllanN PriceC FernándezhernandoMicroRNAs and lipid metabolismCurr Opin Lipidol201728327328010.1097/MOL.000000000000042028333713
  60. KJ RaynerY SuarezA DavalosS ParathathML FitzgeraldN TamehiroEA FisherKJ MooreC Fernández-HernandoMiR-33 contributes to the regulation of cholesterol homeostasisScience201032859851570157310.1126/science.118986220466885
  61. A WagschalSH Najafi-ShoushtariL WangL GoedekeS SinhaGenome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasisNat Med201521111290129710.1038/nm.398026501192
  62. M DragomirP DgeGE MangaGA CălinC VasilescuPatients after splenectomy: old risks and new perspectivesChirurgia2016111539339910.21614/chirurgia.111.5.39327819637
  63. V BronteMJ PittetThe spleen in local and systemic regulation of immunityImmunity201339580681810.1016/j.immuni.2013.10.01024238338
  64. AM MillerD XuDL AsquithL DenbyY LiIL-33 reduces the development of atherosclerosisJ Exp Med2008205233910.1084/jem.2007186818268038
  65. G StollM BendszusInflammation and atherosclerosis: novel insights into plaque formation and destabilizationStroke20063771923193210.1161/01.STR.0000226901.34927.1016741184
  66. N SasakiT YamashitaM TakedaM ShinoharaK NakajimaOral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in miceCirculation2009120221996200510.1161/CIRCULATIONAHA.109.86343119884470
  67. LR PortugalLR FernandesJI Alvarez-LeiteHost cholesterol and inflammation as common key regulators of toxoplasmosis and artherosclerosis developmentExpert Rev Anti-Infect Ther20147780710.1586/eri.09.60
  68. A HermanssonDF KetelhuthD StrodthoffInhibition of T cell response to native low-density lipoprotein reduces atherosclerosisJ Exp Med20102075108110.1084/jem.2009224320439543
  69. FK SwirskiM NahrendorfM EtzrodtM WildgruberV Cortez-RetamozoIdentification of splenic reservoir monocytes and their deployment to inflammatory sitesScience2009325594061261610.1126/science.117520219644120
  70. JM SchröderE ChristophersSecretion of novel and homologous neutrophil-activating peptides by LPS-stimulated human endothelial cellsJ Immunol19891421422442512642504
  71. ML KortelainenK PorvariAdventitial macrophage and lymphocyte accumulation accompanying early stages of human coronary atherogenesisCardiovasc Pathol201423419319710.1016/j.carpath.2014.03.00124685316
  72. AIM-HIGH InvestigatorsThe role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trialAm Heart J2011161353854310.1016/j.ahj.2010.12.00721392609
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6094557/fullTextXML. The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as endocrinology.